Information for continuing education (CE) credit

# COVID-19 Pharmacy Practice Considerations Series - Multisystem Inflammatory Syndrome in Children in COVID-19: Diagnosis, Management, and Relationship to Kawasaki Disease

Activity date: June 11, 2020

Course director: Katrina Harper, PharmD, MBA, BCPS, BCSCP

Vizient is committed to complying with the criteria set forth by the accrediting agencies in order to provide this quality course. To receive credit for educational activities, you must successfully complete all course requirements.

**Requirements**

1. Attend the course in its entirety
2. After the course, you will receive an email with instructions and an access code that you will need to obtain your CE credit
3. Complete the evaluation form no later than July 26, 2020

Upon successful completion of the course requirements, you will be able to print your CE certificate and/or statement of credit for pharmacy education.

**Important note for pharmacists and pharmacy technicians**

All credit awarded to pharmacists must be via CPE Monitor; paper certificates are not valid for submission.  Pharmacists will be able to print individual statements of credit and their transcripts from their NABP e-profile created at [www.mycpemonitor.net](http://www.mycpemonitor.net) or [www.nabp.net](http://www.nabp.net).

1. Please provide an accurate **NABP ID number** and **date of birth** (**mm/dd** – do not include birth year)
2. Vizient will upload your **NABP ID number** and **date of birth** into CPE Monitor after the completion of all steps required to receive credit

If your **NABP ID number** and/or **date of birth** are returned as invalid after the upload, Vizient will make one attempt to contact you for corrections within a 45-day window. After the 45-day window expires, Vizient will not accept the information, and Vizient will not be able to process your CE credit.

**Pharmacist learning objectives**

1. Describe Multisystem Inflammatory Syndrome in Children (MIS-C) and the timing of its onset in relation to SARS-CoV-2 infection.
2. Explain the mechanisms by which viruses can induce autoimmune reactions and the role of immunomodulating agents in the management of MIS-C.
3. Outline Kawasaki disease diagnosis and treatment, relating to MIS-C.
4. Identify ongoing research for pediatric inflammatory syndromes.

**Pharmacy technician learning objectives**

1. Identify immunomodulators that have a potential role in the management of MIS-C.
2. Recall dosing, labeling, and administration information for IVIG.



**Joint Accreditation Statement:**

In support of improving patient care, Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

**Designation Statements:**

#### PHARMACY

Vizient, Inc. designates this activity for a maximum of 1.00 ACPE credit hours.

JA0006103-0000-20-103-L04-P - JA0006103-0000-20-103-L04-T

### CEU

Vizient, Inc. will award CEUs to each participant who successfully completes this program. The CEU is a nationally recognized unit of measure for continuing education and training programs that meet certain criteria (1 contact hour = 0.1 CEU).

**CONFLICT OF INTEREST/CONTENT VALIDATION POLICY:**

As an accredited provider of continuing medical education/continuing education Vizient is dedicated to ensuring balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. Vizient requires all potential faculty and program planners, in advance, to disclose financial relationships with relevant commercial interests. Vizient uses that information to determine whether prospective contributors have potential conflicts of interest. If significant relationships are disclosed, Vizient assesses how those potential conflicts of interest may affect CME/CE content. Vizient requires that all conflicts of interest be resolved prior to participation in the activity. Vizient is committed to resolving potential conflicts of interest, although if contributors have significant relationships that cannot be reconciled, Vizient reserves the right to prohibit participation. Faculty presenters are also expected to disclose any discussion of (1) off-label or investigational uses of FDA approved commercial products or devices or (2) products or devices not yet approved in the United States.

### DISCLOSURE STATEMENTS:

### Current accrediting agency guidelines and Vizient policy state that participants in educational activities should be made aware of any affiliation or financial interest that may affect the presentation and if there will be any discussion of unapproved or investigative use of commercial products/devices. Each planning committee member, reviewer and speaker has completed a Disclosure of Relevant Financial Relationships form.

Relevant financial relationships: None of the planning committee have anything to disclose.

Michael Portman will discuss off-label use of drugs and investigative use of drugs. Please describe: Drugs used to treat Kawasaki disease.

Michelle Rychalsky will discuss off-label use of drugs. Please describe: I will discuss the role of interleukin-1 and interleukin-6 inhibitors (e.g. anakinra, tocilizumab), as well as corticosteroids, for management of Multisystem Inflammatory Syndrome in Children (MIS-C). I will discuss investigative use of drugs. Please describe: I will mention that remdesivir is an antiviral currently available via compassionate and emergency use, and that is currently being studied, for management of SARS-CoV-2 infection in children.

### Planning committee members

Jackie Stokes, BS

Manager, Pharmacy Program Services

Vizient

Gretchen Brummel

PharmD, BCPS

Pharmacy Executive Director

Vizient

Katrina Harper

PharmD, MBA, BCPS, BCSCP

Clinical Pharmacy Director

Vizient

### Course reviewer

Katrina Harper

PharmD, MBA, BCPS, BCSCP

Clinical Pharmacy Director

Vizient

### Presenters

Michael A. Portman, MD

Director, Pediatric Cardiovascular Research

Professor of Pediatrics

Seattle Children’s Hospital

Michelle Rychalsky, PharmD, BCPS

Senior Clinical Pharmacy Specialist

Yale New Haven Children's Hospital